DNA vaccines are a promising therapeutic approach for personalized cancer immunotherapy. However, the application of therapeutic DNA-based cancer vaccines is still limited by their variable clinical results, primarily due to suboptimal antigen selection, backbone plasmid design and the limited transfection efficacy of naked DNA administered by injection.
Evaxion Biotech A/S and a collaborator have successfully concluded a series of large nonrodent animal infection studies testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus. The EVX-B1 antigens were shown to significantly reduce disease burden.
Evaxion Biotech A/S has announced the initiation of a novel pipeline program, EVX-B3, an artificial intelligence (AI)-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be the subject of a co-funded collaboration between Evaxion and an undisclosed partner.
Evaxion Biotech A/S has presented promising results on EVX-B1, a vaccine against Staphylococcus aureus containing antigens identified using artificial intelligence. EVX-B1 induces strong immune responses, both cellular and humoral, that translate to a high level of protection in preclinical models for skin infection and sepsis.
Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
Evaxion Biotech A/S and Pantherna Therapeutics GmbH have announced preclinical proof of concept for the combination of the two companies' key technologies.
Evaxion Biotech A/S, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health (NIH) for the development of a lead vaccine candidate for gonorrhea.
